Recent announcements

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
2021
November
Press Release
24 Nov
2021

POINT Biopharma Licenses Innovative Lu-177 Production Technology from SCK CEN (Belgian Nuclear Research Center)

POINT Biopharma Global Inc. and Studiecentrum voor Kernenergie/Centre d’Etude de l’Energie Nucléaire, also known as the Belgian Nuclear Research Center (“SCK CEN”) today announced a technology license agreement for Lu-177 purification technology to accelerate POINT’s in-house no-carrier-added lutetium-177 (n.c.a. Lu-177) production program.

2021
November
Press Release
22 Nov
2021

POINT Biopharma to Host Virtual Education Event on December 6, 2021

POINT to host inaugural educational event highlighting radiopharmaceuticals, their therapeutic benefit, and commercial considerations. Register online at https://hub.pointbiopharma.com/dec2021.

2021
November
Press Release
12 Nov
2021

POINT Biopharma Reports Third Quarter 2021 Financial Results and Provides Business Update

POINT Biopharma Reports Third Quarter 2021 Financial Results and Provides Business Update: Initiated randomization phase of Phase 3 SPLASH study of PNT2002 in patients with metastatic castration-resistant prostate cancer (mCRPC)...

2021
November
Press Release
9 Nov
2021

POINT Biopharma and IONETIX Announce Ac-225 Supply Agreement

POINT Biopharma Global Inc.(NASDAQ: PNT) and IONETIX Corp announced today a long-term supply agreement for actinium-225 (Ac-225) to support POINT’s validation, drug development, and clinical trials for Ac-225-based radiopharmaceuticals.

2021
October
Press Release
29 Oct
2021

POINT Biopharma and Kinectrics Announce Yb-176 Supply Agreement Enabling North American Production of n.c.a. Lu-177

POINT Biopharma Global Inc. (NASDAQ: PNT) and Kinectrics Inc. announced today a long-term supply agreement for Ytterbium-176 (Yb-176) to support POINT’s in-house no-carrier added Lutetium-177 (n.c.a. Lu-177) production program.

2021
October
Press Release
14 Oct
2021

POINT Biopharma joins Tri-party Collaboration to Advance Ga-68 Imaging Products

ARTMS has entered into a tri-party co-operation with fellow industry leaders, POINT Biopharma and the Canadian Molecular Imaging Probe Consortium (CanProbe), a joint venture between the Centre for Probe Development...

2021
September
Press Release
28 Sep
2021

POINT Biopharma Releases New Data and Exercises Option for Best-in-Class FAP Inhibitor

Unique FAP targeting warhead combined with Actinium-225 or Lutetium-177 demonstrated complete tumor regression and long-term survival in preclinical models. Initiation of a Phase 1 therapeutic clinical trial planned for 1H2022

2021
September
Press Release
23 Sep
2021

POINT Biopharma Announces Initiation of Randomization for its Phase 3 SPLASH study Evaluating PNT2002 for mCRPC

25 patient dosimetry and safety run-in met all pre-specified safety and efficacy criteria, Initiated patient enrollment in Canada with additional countries to begin enrolling in 4Q21.